A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity

While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8(+) T cells. By attempting to potentiate antibody-driven immunity, we found a remarkable synergy between CD4(+) T cells and tumor-binding antibodies. This surprising synergy was mediated by a small subset of tumor-infiltrating CD4(+) T cells that express the high-affinity Fcγ receptor for IgG (FcγRI) in both mouse and human patients. These cells efficiently lyse tumor cells coated with antibodies through concomitant crosslinking of their T cell receptor (TCR) and FcγRI. By expressing FcγRI and its signaling chain in conventional CD4(+) T cells, we successfully employed this mechanism to treat established solid cancers. Overall, this discovery sheds new light on the biology of this T cell subset, their function during tumor immunity, and the means to utilize their unique killing signals in immunotherapy.